Cellectis
CLLS
40 hedge funds and large institutions have $137M invested in Cellectis in 2017 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 7 closing their positions.
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
42% more capital invested
Capital invested by funds: $96.1M → $137M (+$40.8M)
8% more funds holding
Funds holding: 37 → 40 (+3)
0.09% more ownership
Funds ownership: 16.05% → 16.14% (+0.09%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
79% less call options, than puts
Call options by funds: $329K | Put options by funds: $1.54M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.35M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.61M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$300K |
| 4 |
TI
Trexquant Investment
Stamford,
Connecticut
|
+$187K |
| 5 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$178K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$978K |
| 2 |
DA
DSC Advisors
Chicago,
Illinois
|
-$975K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$804K |
| 4 |
Morgan Stanley
New York
|
-$740K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$249K |
CLLS Hedge Fund Activity: Q1 2017 in Review
40 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Cellectis (CLLS) for Q1 2017, worth a combined $137M — up 42% from $96.1M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CLLS positions and 7 closed out — a net gain of 4 holders — while 6 added to existing stakes and 9 trimmed.
The largest buyer was Sphera Funds Management, opening a new position worth an estimated $3.35M. The largest seller was Millennium Management, cutting an estimated $978K.
- 40 institutional investors held Cellectis (CLLS) as of Q1 2017, up from 37 in Q4 2016.
- Funds reported $137M of Cellectis stock for Q1 2017, up 42% quarter-over-quarter.
- 11 funds opened new Cellectis positions in Q1 2017 and 7 closed out, a net change of +4 holders.
- The largest Cellectis buyer in Q1 2017 was Sphera Funds Management, an estimated $3.35M added.
- The largest Cellectis seller in Q1 2017 was Millennium Management, an estimated $978K sold.
Based on aggregated 13F filings for Q1 2017.